Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations

被引：3
作者：
Pelster, M. S. [1 ]
Yaeger, R. [2 ]
Klempner, S. J. [3 ]
Ou, S-H. I. [4 ]
Spira, A. I. [5 ,6 ]
Janne, P. A. [7 ]
Uboha, N. V. [8 ]
Gaffar, Y. A. [9 ]
Newman, G. [10 ]
Paweletz, C. P. [11 ]
Heavey, G. A. [12 ]
Alejandro, L. [13 ]
Kheoh, T. [14 ]
Anderes, K. [15 ]
Torossian, H. Der [16 ]
Christensen, J. G. [17 ]
Weiss, J. [18 ]
机构：
[1] Sarah Cannon Res Inst, Gastrointestinal Res, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[3] Massachusetts Gen Canc Ctr, Dept Med, Boston, MA USA
[4] UCI Hlth Chao Family Comprehens Canc Ctr, Dept Med, Orange, CA USA
[5] Virginia Canc Specialist, Res Inst, Fairfax, VA USA
[6] US Oncol Res, The Woodlands, TX USA
[7] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA
[8] Univ Wisconsin, Med, Madison, TX USA
[9] Maryland Oncol Hematol, Med Oncol, Columbia, MD 8 USA
[10] Ridley Tree Canc Ctr, Clin Res, Santa Barbara, CA USA
[11] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[12] Dana Farber Canc Inst, Belfer Ctr Appl Canc Sci, Boston, MA USA
[13] Mirati Therapeut Inc, Med Affairs, San Diego, CA USA
[14] Mirati Therapeut Inc, Biometr, San Diego, CA USA
[15] Mirati Therapeut Inc, Translat Med & Compan Diagnost, San Diego, CA USA
[16] Mirati Therapeut Inc, Clin Dev, San Diego, CA USA
[17] Mirati Therapeut Inc, San Diego, CA USA
[18] Univ N Carolina, Lineberger Comprehens Canc Ctr, Oncol, Chapel Hill, NC USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1740
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
549O
引用
收藏
页码：S410 / S410
页数：1
相关论文
共 50 条
  • [31] Bioinformatics and Experimental Validation for Identifying Biomarkers Associated with AMG510 (Sotorasib) Resistance in KRASG12C-Mutated Lung Adenocarcinoma
    Lin, Peng
    Cheng, Wei
    Qi, Xin
    Zhang, Pinglu
    Xiong, Jianshe
    Li, Jing
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (03)
  • [32] Natural distribution of genomic alterations correlated with the resistance to KRASG12C inhibitor in Chinese colorectal cancer.
    He, Ke
    Chen, Yuerong
    Liu, Fei
    Li, Liheng
    Wu, Chaosheng
    Lv, Xiu
    Liu, Xinyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15550 - E15550
  • [33] Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC
    Zhang, J.
    Leventakos, K.
    Leal, T. A.
    Pennell, N.
    Barve, M.
    Paulson, A. S.
    Bazhenova, L.
    Johnson, M. L.
    Chao, R. C.
    Velastegui, K.
    Qian, C.
    Bleker, W.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1068 - S1069
  • [34] BAYESIAN PAN-TUMOR MULTILEVEL META-REGRESSION: AN UNANCHORED INDIRECT TREATMENT COMPARISON (ITC) OF ADAGRASIB VERSUS SOTORASIB IN PREVIOUSLY TREATED KRASG12C-MUTATED ADVANCED/METASTATIC SOLID TUMORS
    Maciel, D.
    Bouwmeester, W.
    Korytowsky, B.
    Campbell, H.
    Jevdjevic, M.
    Qian, C.
    Alejandro, L.
    Laurie, M.
    Patel, R.
    Gao, S.
    Jansen, J.
    Cope, S.
    VALUE IN HEALTH, 2024, 27 (06) : S32 - S32
  • [35] Irinotecan- vs. Oxaliplatin-Based Doublets in KRASG12C-Mutated Metastatic Colorectal Cancer-A Multicentre Propensity-Score-Matched Retrospective Analysis
    Formica, Vincenzo
    Morelli, Cristina
    Conca, Veronica
    Calegari, Maria Alessandra
    Lucchetti, Jessica
    Dell'Aquila, Emanuela
    Schirripa, Marta
    Messina, Marco
    Salvatore, Lisa
    Lo Prinzi, Federica
    Dima, Giovanni
    Trovato, Giovanni
    Riondino, Silvia
    Roselli, Mario
    Skoulidis, Ferdinandos
    Arkenau, Hendrik-Tobias
    Cremolini, Chiara
    CANCERS, 2023, 15 (11)
  • [36] Adagrasib Treatment After Sotorasib-Related Hepatotoxicity in Patients With KRASG12C-Mutated Non-Small Cell Lung Cancer: A Case Series and Literature Review (vol 8, e2300644, 2024)
    Luo, Jia
    JCO PRECISION ONCOLOGY, 2024, 8
  • [37] Gene expression correlates of adagrasib response in KRASG12C mutated non-small cell lung cancer (NSCLC)
    Kim, Eejung
    Tong, Xinyuan
    Patel, Ayushi
    Liu, Shengwu
    Dilly, Julien
    Hover, Laura
    Mukhopadhyay, Suman
    Sherman, Fiona
    Christensen, James G.
    Olson, Peter
    Aguirre, Andrew
    Wong, Kwok
    Ji, Hongbin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)
    Ernst, S. M.
    de Bruijn, P.
    van der Horst, T. E.
    Paats, M. S.
    Aerts, J. G.
    Mathijssen, R. H.
    Koolen, S. L.
    Dingemans, A-M. C.
    ANNALS OF ONCOLOGY, 2023, 34
  • [39] AXL activation promotes adaptive resistance to KRAS-G12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Morimoto, Kenji
    Yamada, Tadaaki
    Hirai, Soichi
    Katayama, Yuki
    Kunimasa, Kei
    Sasaki, Takaaki
    Nishida, Makoto
    Watanabe, Satoshi
    Shiotsu, Shinsuke
    Uehara, Hisanori
    Takayama, Koichi
    CANCER RESEARCH, 2024, 84 (06)
  • [40] High EGFR Expression Confers Acquired Resistance to Adagrasib - In Vitro Study Using KRASg12C Mutated Lung Cancer Cells
    Hamada, A.
    Suda, K.
    Obata, K.
    Sato, H.
    Oiki, H.
    Fukuda, S.
    Ohara, S.
    Ito, M.
    Soh, J.
    Tsutani, Y.
    Mitsudomi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S315 - S315
12345